{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T02:16:58Z","timestamp":1783563418074,"version":"3.55.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":52,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100015401","name":"Key Research and Development Program of Shaanxi","doi-asserted-by":"crossref","award":["2022SF-308"],"award-info":[{"award-number":["2022SF-308"]}],"id":[{"id":"10.13039\/501100015401","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"DOI":"10.1186\/s12883-026-04982-7","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T02:04:52Z","timestamp":1779069892000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["BRAF-amplified glioblastoma patients have a worse prognosis than those with BRAF mutation and are associated with amplification of MET, RHEB and CUL1"],"prefix":"10.1186","volume":"26","author":[{"given":"Rong","family":"Da","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maode","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"key":"4982_CR1","doi-asserted-by":"crossref","unstructured":"Gilard V, Tebani A, Dabaj I, Laquerriere A, Fontanilles M, Derrey S, et al. Diagnosis and management of glioblastoma: a comprehensive perspective. J Pers Med. 2021;11(4):258.","DOI":"10.3390\/jpm11040258"},{"issue":"8","key":"4982_CR2","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23(8):1231\u201351.","journal-title":"Neuro Oncol"},{"issue":"11","key":"4982_CR3","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.6004\/jnccn.2020.0052","volume":"18","author":"LB Nabors","year":"2020","unstructured":"Nabors LB, Portnow J, Ahluwalia M, Baehring J, Brem H, Brem S, et al. Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020;18(11):1537\u201370.","journal-title":"J Natl Compr Canc Netw."},{"issue":"suppl_5","key":"4982_CR4","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/now207","volume":"18","author":"QT Ostrom","year":"2016","unstructured":"Ostrom QT, Gittleman H, Xu J, Kromer C, Wolinsky Y, Kruchko C, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2009\u20132013. Neuro Oncol. 2016;18(suppl_5):v1\u201375.","journal-title":"Neuro Oncol."},{"issue":"6892","key":"4982_CR5","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949\u201354.","journal-title":"Nature"},{"issue":"1","key":"4982_CR6","doi-asserted-by":"publisher","first-page":"19999","DOI":"10.1038\/s41598-021-99278-w","volume":"11","author":"SN McNulty","year":"2021","unstructured":"McNulty SN, Schwetye KE, Ferguson C, Storer CE, Ansstas G, Kim AH, et al. BRAF mutations may identify a clinically distinct subset of glioblastoma. Sci Rep. 2021;11(1):19999.","journal-title":"Sci Rep"},{"issue":"2","key":"4982_CR7","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","volume":"155","author":"CW Brennan","year":"2013","unstructured":"Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155(2):462\u201377.","journal-title":"Cell"},{"key":"4982_CR8","doi-asserted-by":"publisher","first-page":"772052","DOI":"10.3389\/fonc.2021.772052","volume":"11","author":"V Bouche","year":"2021","unstructured":"Bouche V, Aldegheri G, Donofrio CA, Fioravanti A, Roberts-Thomson S, Fox SB, et al. BRAF signaling inhibition in glioblastoma: which clinical perspectives? Front Oncol. 2021;11:772052.","journal-title":"Front Oncol"},{"issue":"5","key":"4982_CR9","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401\u20134.","journal-title":"Cancer Discov"},{"issue":"269","key":"4982_CR10","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1.","journal-title":"Sci Signal"},{"issue":"23","key":"4982_CR11","doi-asserted-by":"publisher","first-page":"3861","DOI":"10.1158\/0008-5472.CAN-23-0816","volume":"83","author":"I de Bruijn","year":"2023","unstructured":"de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, et al. Analysis and visualization of longitudinal genomic and clinical data from the AACR Project GENIE Biopharma Collaborative in cBioPortal. Cancer Res. 2023;83(23):3861\u20137.","journal-title":"Cancer Res"},{"issue":"2","key":"4982_CR12","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.cell.2018.03.022","volume":"173","author":"KA Hoadley","year":"2018","unstructured":"Hoadley KA, Yau C, Hinoue T, Wolf DM, Lazar AJ, Drill E, et al. Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell. 2018;173(2):291-304 e6.","journal-title":"Cell."},{"issue":"3","key":"4982_CR13","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cels.2018.03.002","volume":"6","author":"K Ellrott","year":"2018","unstructured":"Ellrott K, Bailey MH, Saksena G, Covington KR, Kandoth C, Stewart C, et al. Scalable open science approach for mutation calling of tumor exomes using multiple genomic pipelines. Cell Syst. 2018;6(3):271-81 e7.","journal-title":"Cell Syst."},{"issue":"4","key":"4982_CR14","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.ccell.2018.03.007","volume":"33","author":"AM Taylor","year":"2018","unstructured":"Taylor AM, Shih J, Ha G, Gao GF, Zhang X, Berger AC, et al. Genomic and Functional Approaches to Understanding Cancer Aneuploidy. Cancer Cell. 2018;33(4):676-89 e3.","journal-title":"Cancer Cell."},{"issue":"2","key":"4982_CR15","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.cell.2018.02.052","volume":"173","author":"J Liu","year":"2018","unstructured":"Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, et al. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell. 2018;173(2):400-16 e11.","journal-title":"Cell."},{"issue":"2","key":"4982_CR16","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","volume":"173","author":"F Sanchez-Vega","year":"2018","unstructured":"Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, et al. Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell. 2018;173(2):321-37 e10.","journal-title":"Cell."},{"issue":"1","key":"4982_CR17","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.celrep.2018.03.050","volume":"23","author":"Q Gao","year":"2018","unstructured":"Gao Q, Liang WW, Foltz SM, Mutharasu G, Jayasinghe RG, Cao S, et al. Driver Fusions and Their Implications in the Development and Treatment of Human Cancers. Cell Rep. 2018;23(1):227-38 e3.","journal-title":"Cell Rep."},{"issue":"2","key":"4982_CR18","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/s41588-018-0318-2","volume":"51","author":"V Bhandari","year":"2019","unstructured":"Bhandari V, Hoey C, Liu LY, Lalonde E, Ray J, Livingstone J, et al. Molecular landmarks of tumor hypoxia across cancer types. Nat Genet. 2019;51(2):308\u201318.","journal-title":"Nat Genet"},{"issue":"7800","key":"4982_CR19","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41586-020-2095-1","volume":"579","author":"GD Poore","year":"2020","unstructured":"Poore GD, Kopylova E, Zhu Q, Carpenter C, Fraraccio S, Wandro S, et al. Microbiome analyses of blood and tissues suggest cancer diagnostic approach. Nature. 2020;579(7800):567\u201374.","journal-title":"Nature"},{"issue":"2","key":"4982_CR20","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.cell.2018.03.033","volume":"173","author":"L Ding","year":"2018","unstructured":"Ding L, Bailey MH, Porta-Pardo E, Thorsson V, Colaprico A, Bertrand D, et al. Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. Cell. 2018;173(2):305-20 e10.","journal-title":"Cell."},{"key":"4982_CR21","doi-asserted-by":"crossref","unstructured":"Bonneville R, Krook MA, Kautto EA, Miya J, Wing MR, Chen HZ, et al. Landscape of microsatellite instability across 39 cancer types. JCO Precis Oncol. 2017;1(1):1\u201315.","DOI":"10.1200\/PO.17.00073"},{"issue":"12","key":"4982_CR22","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1016\/j.cell.2022.04.038","volume":"185","author":"FS Varn","year":"2022","unstructured":"Varn FS, Johnson KC, Martinek J, Huse JT, Nasrallah MP, Wesseling P, et al. Glioma progression is shaped by genetic evolution and microenvironment interactions. Cell. 2022;185(12):2184-99 e16.","journal-title":"Cell"},{"issue":"5","key":"4982_CR23","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1158\/0008-5472.CAN-23-2093","volume":"84","author":"TM Malta","year":"2024","unstructured":"Malta TM, Sabedot TS, Morosini NS, Datta I, Garofano L, Vallentgoed W, et al. The Epigenetic Evolution of Glioma Is Determined by the IDH1 Mutation Status and Treatment Regimen. Cancer Res. 2024;84(5):741\u201356.","journal-title":"Cancer Res"},{"issue":"7785","key":"4982_CR24","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41586-019-1775-1","volume":"576","author":"FP Barthel","year":"2019","unstructured":"Barthel FP, Johnson KC, Varn FS, Moskalik AD, Tanner G, Kocakavuk E, et al. Longitudinal molecular trajectories of diffuse glioma in adults. Nature. 2019;576(7785):112\u201320.","journal-title":"Nature"},{"issue":"18","key":"4982_CR25","doi-asserted-by":"publisher","first-page":"5537","DOI":"10.1158\/1078-0432.CCR-19-0032","volume":"25","author":"P Jonsson","year":"2019","unstructured":"Jonsson P, Lin AL, Young RJ, DiStefano NM, Hyman DM, Li BT, et al. Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas. Clin Cancer Res. 2019;25(18):5537\u201347.","journal-title":"Clin Cancer Res"},{"issue":"7741","key":"4982_CR26","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41586-019-0882-3","volume":"565","author":"AM Miller","year":"2019","unstructured":"Miller AM, Shah RH, Pentsova EI, Pourmaleki M, Briggs S, Distefano N, et al. Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid. Nature. 2019;565(7741):654\u20138.","journal-title":"Nature"},{"issue":"1","key":"4982_CR27","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1158\/1078-0432.CCR-23-1180","volume":"30","author":"A Bhatia","year":"2024","unstructured":"Bhatia A, Moreno R, Reiner AS, Nandakumar S, Walch HS, Thomas TM, et al. Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma. Clin Cancer Res. 2024;30(1):106\u201315.","journal-title":"Clin Cancer Res"},{"issue":"6167","key":"4982_CR28","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1126\/science.1239947","volume":"343","author":"BE Johnson","year":"2014","unstructured":"Johnson BE, Mazor T, Hong C, Barnes M, Aihara K, McLean CY, et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science. 2014;343(6167):189\u201393.","journal-title":"Science"},{"issue":"3","key":"4982_CR29","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.cell.2015.12.028","volume":"164","author":"M Ceccarelli","year":"2016","unstructured":"Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, et al. Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell. 2016;164(3):550\u201363.","journal-title":"Cell"},{"issue":"5","key":"4982_CR30","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1158\/1078-0432.CCR-19-0909","volume":"26","author":"RA Vaubel","year":"2020","unstructured":"Vaubel RA, Tian S, Remonde D, Schroeder MA, Mladek AC, Kitange GJ, et al. Genomic and phenotypic characterization of a broad panel of patient-derived xenografts reflects the diversity of glioblastoma. Clin Cancer Res. 2020;26(5):1094\u2013104.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"4982_CR31","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ccell.2021.01.006","volume":"39","author":"LB Wang","year":"2021","unstructured":"Wang LB, Karpova A, Gritsenko MA, Kyle JE, Cao S, Li Y, et al. Proteogenomic and metabolomic characterization of human glioblastoma. Cancer Cell. 2021;39(4):509-28 e20.","journal-title":"Cancer Cell"},{"issue":"3","key":"4982_CR32","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41591-019-0349-y","volume":"25","author":"J Zhao","year":"2019","unstructured":"Zhao J, Chen AX, Gartrell RD, Silverman AM, Aparicio L, Chu T, et al. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nat Med. 2019;25(3):462\u20139.","journal-title":"Nat Med"},{"issue":"7216","key":"4982_CR33","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/nature07385","volume":"455","author":"Cancer Genome Atlas Research N","year":"2008","unstructured":"Cancer Genome Atlas Research N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061\u20138.","journal-title":"Nature"},{"issue":"10","key":"4982_CR34","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1093\/neuonc\/nox086","volume":"19","author":"AA Thomas","year":"2017","unstructured":"Thomas AA, Abrey LE, Terziev R, Raizer J, Martinez NL, Forsyth P, et al. Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma. Neuro Oncol. 2017;19(10):1380\u201390.","journal-title":"Neuro Oncol"},{"issue":"9829","key":"4982_CR35","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1016\/S0140-6736(12)60398-5","volume":"379","author":"GS Falchook","year":"2012","unstructured":"Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet. 2012;379(9829):1893\u2013901.","journal-title":"Lancet"},{"issue":"6","key":"4982_CR36","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S0092-8674(04)00215-6","volume":"116","author":"PT Wan","year":"2004","unstructured":"Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004;116(6):855\u201367.","journal-title":"Cell"},{"key":"4982_CR37","doi-asserted-by":"publisher","first-page":"522816","DOI":"10.3389\/fonc.2020.522816","volume":"10","author":"C Qin","year":"2020","unstructured":"Qin C, Long W, Zhang C, Xie Y, Wu C, Li Y, et al. Multidisciplinary therapy managed recurrent Glioblastoma in a BRAF-V600E mutant pregnant female: a case report and review of the literature. Front Oncol. 2020;10:522816.","journal-title":"Front Oncol"},{"key":"4982_CR38","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/1471-2407-14-258","volume":"14","author":"GW Robinson","year":"2014","unstructured":"Robinson GW, Orr BA, Gajjar A. Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy. BMC Cancer. 2014;14:258.","journal-title":"BMC Cancer"},{"key":"4982_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.17.00055","volume":"1","author":"K Beba Abadal","year":"2017","unstructured":"Beba Abadal K, Walsh MA, Yachnis AT, Tran DD, Ghiaseddin AP. Eleven Month Progression-Free Survival on Vemurafenib Monotherapy in a Patient With Recurrent and Metastatic BRAF V600E-Mutated Glioblastoma WHO Grade 4. JCO Precis Oncol. 2017;1:1\u20135.","journal-title":"JCO Precis Oncol"},{"issue":"35","key":"4982_CR40","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1200\/JCO.2018.78.9990","volume":"36","author":"T Kaley","year":"2018","unstructured":"Kaley T, Touat M, Subbiah V, Hollebecque A, Rodon J, Lockhart AC, et al. BRAF Inhibition in BRAF(V600)-Mutant Gliomas: Results From the VE-BASKET Study. J Clin Oncol. 2018;36(35):3477\u201384.","journal-title":"J Clin Oncol"},{"issue":"24","key":"4982_CR41","doi-asserted-by":"publisher","first-page":"7294","DOI":"10.1158\/1078-0432.CCR-17-3572","volume":"25","author":"MW Kieran","year":"2019","unstructured":"Kieran MW, Geoerger B, Dunkel IJ, Broniscer A, Hargrave D, Hingorani P, et al. A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory BRAF V600 Mutation-Positive Solid Tumors. Clin Cancer Res. 2019;25(24):7294\u2013302.","journal-title":"Clin Cancer Res"},{"key":"4982_CR42","doi-asserted-by":"crossref","unstructured":"Schreck KC, Grossman SA, Pratilas CA. BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors. Cancers (Basel). 2019;11(9):1262.","DOI":"10.3390\/cancers11091262"},{"issue":"9","key":"4982_CR43","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1200\/JCO.2014.58.3922","volume":"33","author":"M Mistry","year":"2015","unstructured":"Mistry M, Zhukova N, Merico D, Rakopoulos P, Krishnatry R, Shago M, et al. BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma. J Clin Oncol. 2015;33(9):1015\u201322.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4982_CR44","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s12883-021-02224-6","volume":"21","author":"W Wang","year":"2021","unstructured":"Wang W, Wang M, Jiang H, Wang T, Da R. BRAF(non-V600E) more frequently co-occurs with IDH1\/2 mutations in adult patients with gliomas than in patients harboring BRAF(V600E) but without a survival advantage. BMC Neurol. 2021;21(1):195.","journal-title":"BMC Neurol"},{"issue":"Suppl 5(Suppl 5","key":"4982_CR45","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/nos218","volume":"14","author":"TA Dolecek","year":"2012","unstructured":"Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol. 2012;14(Suppl 5(Suppl 5)):v1-49.","journal-title":"Neuro Oncol"},{"issue":"8","key":"4982_CR46","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1101\/gad.187922.112","volume":"26","author":"GP Dunn","year":"2012","unstructured":"Dunn GP, Rinne ML, Wykosky J, Genovese G, Quayle SN, Dunn IF, et al. Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev. 2012;26(8):756\u201384.","journal-title":"Genes Dev"},{"issue":"5","key":"4982_CR47","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1111\/bpa.12566","volume":"28","author":"A Korshunov","year":"2018","unstructured":"Korshunov A, Chavez L, Sharma T, Ryzhova M, Schrimpf D, Stichel D, et al. Epithelioid glioblastomas stratify into established diagnostic subsets upon integrated molecular analysis. Brain Pathol. 2018;28(5):656\u201362.","journal-title":"Brain Pathol"},{"issue":"5","key":"4982_CR48","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1097\/PAS.0b013e31827f9c5e","volume":"37","author":"BK Kleinschmidt-DeMasters","year":"2013","unstructured":"Kleinschmidt-DeMasters BK, Aisner DL, Birks DK, Foreman NK. Epithelioid GBMs show a high percentage of BRAF V600E mutation. Am J Surg Pathol. 2013;37(5):685\u201398.","journal-title":"Am J Surg Pathol"},{"issue":"23","key":"4982_CR49","doi-asserted-by":"publisher","first-page":"7137","DOI":"10.1158\/0008-5472.CAN-11-1243","volume":"71","author":"J Villanueva","year":"2011","unstructured":"Villanueva J, Vultur A, Herlyn M. Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options. Cancer Res. 2011;71(23):7137\u201340.","journal-title":"Cancer Res"},{"issue":"4","key":"4982_CR50","doi-asserted-by":"publisher","first-page":"343","DOI":"10.6004\/jnccn.2017.7052","volume":"16","author":"KC Schreck","year":"2018","unstructured":"Schreck KC, Guajardo A, Lin DDM, Eberhart CG, Grossman SA. Concurrent BRAF\/MEK inhibitors in BRAF V600-mutant high-grade primary brain tumors. J Natl Compr Canc Netw. 2018;16(4):343\u20137.","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"4982_CR51","doi-asserted-by":"publisher","first-page":"4","DOI":"10.6004\/jnccn.2017.7032","volume":"16","author":"TM Johanns","year":"2018","unstructured":"Johanns TM, Ferguson CJ, Grierson PM, Dahiya S, Ansstas G. Rapid clinical and radiographic response with combined Dabrafenib and Trametinib in adults with BRAF-mutated high-grade glioma. J Natl Compr Canc Netw. 2018;16(1):4\u201310.","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"4982_CR52","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.3171\/2018.12.JNS182700","volume":"132","author":"BD Choi","year":"2020","unstructured":"Choi BD, Lee DK, Yang JC, Ayinon CM, Lee CK, Maus D, et al. Receptor tyrosine kinase gene amplification is predictive of intraoperative seizures during glioma resection with functional mapping. J Neurosurg. 2020;132(4):1017\u201323.","journal-title":"J Neurosurg"},{"issue":"1","key":"4982_CR53","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s11060-012-0938-9","volume":"110","author":"AS Chi","year":"2012","unstructured":"Chi AS, Batchelor TT, Dias-Santagata D, Borger D, Stiles CD, Wang DL, et al. Prospective, high-throughput molecular profiling of human gliomas. J Neurooncol. 2012;110(1):89\u201398.","journal-title":"J Neurooncol"},{"key":"4982_CR54","doi-asserted-by":"publisher","first-page":"531968","DOI":"10.3389\/fonc.2020.531968","volume":"10","author":"R Da","year":"2021","unstructured":"Da R, Wang M, Jiang H, Wang T, Wang W. BRAFAMP frequently co-occurs with IDH1\/2, TP53, and ATRX mutations in adult patients with gliomas and is associated with poorer survival than that of patients harboring BRAFV600E. Front Oncol. 2021;10:531968.","journal-title":"Front Oncol"},{"key":"4982_CR55","doi-asserted-by":"publisher","first-page":"1254955","DOI":"10.3389\/fmed.2023.1254955","volume":"10","author":"P Ghanem","year":"2023","unstructured":"Ghanem P, Fatteh M, Kamson DO, Balan A, Chang M, Tao J, et al. Druggable genomic landscapes of high-grade gliomas. Front Med (Lausanne). 2023;10:1254955.","journal-title":"Front Med (Lausanne)"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-026-04982-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-04982-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-04982-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T02:02:23Z","timestamp":1783562543000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12883-026-04982-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4982"],"URL":"https:\/\/doi.org\/10.1186\/s12883-026-04982-7","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]},"assertion":[{"value":"24 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All data collected and generated from TCGA, which is a public database, and we strictly followed TCGA publication guidelines (\n                      \n                      ).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"441"}}